Comparing HCC cell lines treated with Ezetimibe to control HCC cells, NPC1L1 expression was significantly downregulated (Figure 6C), confirming that NPC1L1 is indeed a target of Ezetimibe in HCC cells. The gene discussed is NPC1L1; the disease is hepatocellular carcinoma.